Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.39 |
| ▸ | CDK4 | P11802 | 4/20 | 0.38 |
| ▸ | CCND1 | P24385 | 4/20 | 0.38 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3259098 | 0.78 | SLC6A4 (0.43) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL6100232 | 0.78 | SLC6A4 (0.46) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL17818472 | 0.75 | SLC6A4 (0.46) | SLC6A4SLC6A2CDK4CCND1BIRC5 | |
| SCHEMBL9696657 | 0.74 | SLC6A4 (0.37) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL9337141 | 0.74 | KMT2A (0.44) | SLC6A4SLC6A2 | |
| SCHEMBL22449509 | 0.71 | SLC6A2 (0.40) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL27575336 | 0.71 | SLC6A2 (0.45) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL10643066 | 0.70 | SLC6A4 (0.57) | SLC6A4SLC6A2 | |
| SCHEMBL9235062 | 0.70 | SLC6A4 (0.35) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL13892321 | 0.70 | CDK4 (0.45) | SLC6A4SLC6A2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | SLC6A4 438/4885SLC6A2 331/4885CDK4 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.